Viridian Therapeutics, Inc.\DE - FORM S-1 - EX-3.1 - EXHIBIT 3.1 - March 18, 2014

Attached files

file filename
S-1 - S-1 - Viridian Therapeutics, Inc.\DEv369400_s1.htm
EX-3.5 - EXHIBIT 3.5 - Viridian Therapeutics, Inc.\DEv369400_ex3-5.htm
EX-4.1 - EXHIBIT 4.1 - Viridian Therapeutics, Inc.\DEv369400_ex4-1.htm
EX-1.1 - EXHIBIT 1.1 - Viridian Therapeutics, Inc.\DEv369400_ex1-1.htm
EX-3.6 - EXHIBIT 3.6 - Viridian Therapeutics, Inc.\DEv369400_ex3-6.htm
EX-3.2 - EXHIBIT 3.2 - Viridian Therapeutics, Inc.\DEv369400_ex3-2.htm
EX-3.3 - EXHIBIT 3.3 - Viridian Therapeutics, Inc.\DEv369400_ex3-3.htm
EX-10.8 - EXHIBIT 10.8 - Viridian Therapeutics, Inc.\DEv369400_ex10-8.htm
EX-99.2 - EXHIBIT 99.2 - Viridian Therapeutics, Inc.\DEv369400_ex99-2.htm
EX-23.1 - EXHIBIT 23.1 - Viridian Therapeutics, Inc.\DEv369400_ex23-1.htm
EX-99.3 - EXHIBIT 99.3 - Viridian Therapeutics, Inc.\DEv369400_ex99-3.htm
EX-10.7 - EXHIBIT 10.7 - Viridian Therapeutics, Inc.\DEv369400_ex10-7.htm
EX-10.2 - EXHIBIT10.2 - Viridian Therapeutics, Inc.\DEv369400_ex10-2.htm
EX-10.3 - EXHIBIT 10.3 - Viridian Therapeutics, Inc.\DEv369400_ex10-3.htm
EX-10.1 - EXHIBIT 10.1 - Viridian Therapeutics, Inc.\DEv369400_ex10-1.htm
EX-21.1 - EXHIBIT 21.1 - Viridian Therapeutics, Inc.\DEv369400_ex21-1.htm
EX-10.5 - EXHIBIT 10.5 - Viridian Therapeutics, Inc.\DEv369400_ex10-5.htm
EX-10.4 - EXHIBIT 10.4 - Viridian Therapeutics, Inc.\DEv369400_ex10-4.htm
EX-10.6 - EXHIBIT 10.6 - Viridian Therapeutics, Inc.\DEv369400_ex10-6.htm
EX-99.1 - EXHIBIT 99.1 - Viridian Therapeutics, Inc.\DEv369400_ex99-1.htm
EX-10.13 - EXHIBIT 10.13 - Viridian Therapeutics, Inc.\DEv369400_ex10-13.htm
EX-10.12 - EXHIBIT 10.12 - Viridian Therapeutics, Inc.\DEv369400_ex10-12.htm
EX-10.11 - EXHIBIT 10.11 - Viridian Therapeutics, Inc.\DEv369400_ex10-11.htm
EX-10.10 - EXHIBIT 10.10 - Viridian Therapeutics, Inc.\DEv369400_ex10-10.htm
EX-10.14 - EXHIBIT 10.14 - Viridian Therapeutics, Inc.\DEv369400_ex10-14.htm
EX-10.15 - EXHIBIT 10.15 - Viridian Therapeutics, Inc.\DEv369400_ex10-15.htm
EX-10.2.1 - EXHIBIT 10.2.1 - Viridian Therapeutics, Inc.\DEv369400_ex10-2x1.htm
EX-10.3.1 - EXHIBIT 10.3.1 - Viridian Therapeutics, Inc.\DEv369400_ex10-3x1.htm
EX-10.9 - EXHIBIT 10.9 - Viridian Therapeutics, Inc.\DEv369400_ex10-9.htm

  Delaware PAGE 1
  The First State  

 

 

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF FORMATION OF “SIGNAL GENETICS LLC”, FILED IN THIS OFFICE ON THE EIGHTH DAY OF DECEMBER, A.D. 2010, AT 6:20 O’CLOCK P.M.

 

       
     
    /s/ Jeffrey W. Bullock
    Jeffrey W. Bullock, Secretary of State
4910486 8100   AUTHENTICATION: 8415030
     
101165226   DATE 12-09-10
You may verify this certificate online    
at corp.delaware.gov/authver.shtml      

  

 
 

 

  State of Delaware
  Secretary of State
  Division of Corporations
  Delivered 06:20 PM 12/08/2010
  FILED 06:20 PM 12/08/2010
  SRV 101165226 – 4910486 FILE

  

CERTIFICATE OF FORMATION

 

OF

 

SIGNAL GENETICS LLC

 

The undersigned, an authorized natural person, for the purpose of forming a limited liability company, under the provisions and subject to the requirements of the State of Delaware (particularly Chapter 18, Title 6 of the Delaware Code and the acts amendatory thereof and supplemental thereto, and known, identified, and referred to as the “Delaware Limited Liability Company Act”), hereby certifies that:

 

FIRST: The name of the limited liability company (hereinafter called the “Limited Liability Company’) is:

 

Signal Genetics LLC

 

SECOND: The address of the registered office and the name and the address of the registered agent of the Limited Liability Company required to be maintained by Section 18-104 of the Delaware Limited Liability Company Act are:

 

Corporation Service Company
2711 Centerville Road, Suite 400
Wilmington, Delaware 19808

 

Executed on September 21, 2010.

 

  /s/ John E. Andrews
  John E. Andrews
  Authorized Person

 

 

 

Viridian Therapeutics, Inc.\DE Reports